Observational Studies of Statins in Systolic Heart Failure

Heart Failure Clinics

Volumn 4, Issue 2, 2008, Pages 201-208

  Levy, Wayne C ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; AMIODARONE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BOSENTAN; BUCINDOLOL; C REACTIVE PROTEIN; CAPTOPRIL; CELACADE; CERIVASTATIN; CHOLESTEROL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ETANERCEPT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOMODULATING AGENT; INFLIXIMAB; LOSARTAN; MEVINOLIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; UNCLASSIFIED DRUG; VALSARTAN;

ACUTE HEART INFARCTION; ANTIINFLAMMATORY ACTIVITY; CARDIAC RESYNCHRONIZATION THERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DEFIBRILLATOR; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG USE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HOSPITALIZATION; HUMAN; HYPERCHOLESTEROLEMIA; LIFE EXPECTANCY; LOW DRUG DOSE; META ANALYSIS; MONOTHERAPY; MORTALITY; NONHUMAN; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SYSTEMATIC REVIEW; SYSTOLIC HEART FAILURE; TREATMENT FAILURE; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; HEART FAILURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; SYSTOLE;

EID: 42149183168     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2008.01.006     Document Type: Review

References (42)

1. Levy W.C., Mozaffarian D., Linker D.T., et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation 113 11 (2006) 1424-1433
2. Kirkby N.S., Hadoke P.W., Bagnall A.J., et al. The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house?. Br J Pharmacol (2007) [epub ahead of print]
3. Mann D.L., McMurray J.J., Packer M., et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109 13 (2004) 1594-1602
4. Chung E.S., Packer M., Lo K.H., et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107 25 (2003) 3133-3140
5. ACCLAIM-Preliminary Trial Results. Available at:. http://www.vasogen.com/sec/clinical_chronic Accessed November 21, 2007
6. Takemoto M., and Liao J.K. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 21 11 (2001) 1712-1719
7. Fraccarollo D., Galuppo P., Hildemann S., et al. Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction. J Am Coll Cardiol 42 9 (2003) 1666-1673
8. Bauersachs J., Galuppo P., Fraccarollo D., et al. Improvement of left ventricular remodeling and function by hydroxymethylglutarylcoenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation 104 9 (2001) 982-985
9. Lowes B.D., Gilbert E.M., Abraham W.T., et al. Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N Engl J Med 346 18 (2002) 1357-1365
10. Bleske B.E., Nicklas J.M., Bard R.L., et al. Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein level. J Am Coll Cardiol 47 2 (2006) 338-341
11. Kjekshus J., Dunselman P., Blideskog M., et al. A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics. Eur J Heart Fail 7 6 (2005) 1059-1069
12. Node K., Fujita M., Kitakaze M., et al. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 108 7 (2003) 839-843
13. Sola S., Mir M.Q., Lerakis S., et al. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol 47 2 (2006) 332-337
14. Krum H., Ashton E., Reid C., et al. Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure. J Card Fail 13 1 (2007) 1-7
15. Jialal I., Stein D., Balis D., et al. Effect of hydroxymethylglutarylcoenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 103 15 (2001) 1933-1935
16. Zwaka T.P., Hombach V., and Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 103 9 (2001) 1194-1197
17. Anand I.S., Latini R., Florea V.G., et al. C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation 112 10 (2005) 1428-1434
18. Nickenig G., Baumer A.T., Temur Y., et al. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation 100 21 (1999) 2131-2134
19. Kinlay S., Schwartz G.G., Olsson A.G., et al. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation 108 13 (2003) 1560-1566
20. Executive summary of the third report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 285 19 (2001) 2486-2497
21. Kjekshus J., Pedersen T.R., Olsson A.G., et al. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail 3 4 (1997) 249-254
22. Athyros V.G., Papageorgiou A.A., Mercouris B.R., et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus usual care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 18 4 (2002) 220-228
23. Athyros V.G., Elisaf M., Papageorgiou A.A., et al. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Am J Kidney Dis 43 4 (2004) 589-599
24. Scirica B.M., Morrow D.A., Cannon C.P., et al. Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study. J Am Coll Cardiol 47 11 (2006) 2326-2331
25. Khush K.K., Waters D.D., Bittner V., et al. Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study. Circulation 115 5 (2007) 576-583
26. Mozaffarian D., Nye R., and Levy W.C. Statin therapy is associated with lower mortality among patients with severe heart failure. Am J Cardiol 93 9 (2004) 1124-1129
27. Anker S.D., Clark A.L., Winkler R., et al. Statin use and survival in patients with chronic heart failure: results from two observational studies with 5200 patients. Int J Cardiol 112 2 (2006) 234-242
28. Krum H., Latini R., Maggioni A.P., et al. Statins and symptomatic chronic systolic heart failure: a post-hoc analysis of 5010 patients enrolled in Val-HeFT. Int J Cardiol (2006)
29. Krum H., Bailey M., Meyer W., et al. Impact of statin therapy on clinical outcomes in chronic heart failure patients according to beta-blocker use: results of CIBIS II. Cardiology 108 1 (2007) 28-34
30. Domanski M., Coady S., Fleg J., et al. Effect of statin therapy on survival in patients with nonischemic dilated cardiomyopathy (from the Beta-blocker Evaluation of Survival Trial [BEST]). Am J Cardiol 99 10 (2007) 1448-1450
31. Hognestad A., Dickstein K., Myhre E., et al. Effect of combined statin and beta-blocker treatment on one-year morbidity and mortality after acute myocardial infarction associated with heart failure. Am J Cardiol 93 5 (2004) 603-606
32. Mitchell L.B., Powell J.L., Gillis A.M., et al. Are lipid-lowering drugs also antiarrhythmic drugs? An analysis of the Antiarrhythmics versus Implantable Defibrillators (AVID) trial. J Am Coll Cardiol 42 1 (2003) 81-87
33. Goldberger J.J., Subacius H., Schaechter A., et al. Effects of statin therapy on arrhythmic events and survival in patients with nonischemic dilated cardiomyopathy. J Am Coll Cardiol 48 6 (2006) 1228-1233
34. Vyas A.K., Guo H., Moss A.J., et al. Reduction in ventricular tachyarrhythmias with statins in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol 47 4 (2006) 769-773
35. Dickinson M.G., Ip J.H., Olshansky B., et al. Statin use was associated with reduced mortality in both ischemic and nonischemic cardiomyopathy and in patients with implantable defibrillators: mortality data and mechanistic insights from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Am Heart J 153 4 (2007) 573-578
36. Sumner A.D., Boehmer J., Saxon L.A., et al. Statin use is associated with a marked improvement in survival in an advanced heart failure population from the COMPANION trial. J Am Coll Cardiol 45 3 (2005) 183A
37. Kjekshus J., Apetrei E., Barrios V., et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med (2007)
38. Ramasubbu K., Estep J., White D.L., et al. Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy. J Am Coll Cardiol 51 4 (2008) 415-426
39. Studer M., Briel M., Leimenstoll B., et al. Effect of different antilipidemic agents and diets on mortality: a systematic review. Arch Intern Med 165 7 (2005) 725-730
40. Laufs U., Wassmann S., Schackmann S., et al. Beneficial effects of statins in patients with non-ischemic heart failure. Z Kardiol 93 2 (2004) 103-108
41. Mozaffarian D., Minami E., Letterer R.A., et al. The effects of atorvastatin (10 mg) on systemic inflammation in heart failure. Am J Cardiol 96 12 (2005) 1699-1704
42. Vrtovec B., Okrajsek R., Golicnik A., et al. Atorvastatin therapy decreases sudden cardiac death in patients with advanced chronic heart failure: a prospective study. [abstract 3195] (2007), European Society of Cardiology Congress, Vienna (Austria)